Monopar Therapeutics (MNPR) — 10-Q Filings

All 10-Q filings from Monopar Therapeutics. Browse 4 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (4)

Monopar's Cash Soars Post-Offering, Losses Widen Amid Program Shift — Nov 13, 2025 Risk: high
Monopar Therapeutics Inc. reported a significant increase in cash and cash equivalents to $127,677,360 as of September 30, 2025, up from $45,816,289 at December
Monopar's Q2 Net Loss Narrows to $81,932 Amidst Reverse Stock Split — Aug 12, 2025 Risk: high
Monopar Therapeutics reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage as a pharmaceutical company.
Monopar Therapeutics Q2 2024 10-Q Filed — Aug 9, 2024 Risk: medium
Monopar Therapeutics filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $17,601,827 as of June 30, 2024. The
Monopar Therapeutics Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
Monopar Therapeutics (MNPR) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Monopar Therapeutics reported cash and cash equivalents of $17,484,175

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX